TPM
VRTX icon

Triasima Portfolio Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Triasima Portfolio Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,213
Closed -$3.01M – 167
2025
Q1 		$3.01M Sell
6,213
-5,447
-47% -$2.54M 0.59% 58
2024
Q4 		$4.7M Buy
11,660
+127
+1% +$58.9K 0.91% 32
2024
Q3 		$5.36M Buy
11,533
+28
+0.2% +$13.4K 1.21% 26
2024
Q2 		$5.39M Buy
11,505
+3
+0% +$1.3K 0.49% 41
2024
Q1 		$4.81M Sell
11,502
-1,303
-10% -$551K 0.4% 48
2023
Q4 		$5.21M Sell
12,805
-2,227
-15% -$823K 0.43% 45
2023
Q3 		$5.23M Buy
15,032
+1,101
+8% +$385K 0.48% 43
2023
Q2 		$6.49M Buy
13,931
+2,715
+24% +$915K 0.41% 46
2023
Q1 		$3.53M Sell
11,216
-8,773
-44% -$2.63M 0.29% 57
2022
Q4 		$5.77M Buy
19,989
+1,389
+7% +$423K 0.44% 40
2022
Q3 		$5.38M Buy
18,600
+9,610
+107% +$2.76M 0.44% 41
2022
Q2 		$2.53M Buy
+8,990
New +$2.41M 0.18% 68

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Triasima Portfolio Management's VRTX Position: Q2 2025 in Review

Triasima Portfolio Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 6,213 shares — an estimated $3.01M sold.

Triasima Portfolio Management first reported a position in VRTX in Q2 2022 and held it in 12 quarters. The position peaked at $6.49M in Q2 2023. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • Triasima Portfolio Management reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Triasima Portfolio Management sold 6,213 Vertex Pharmaceuticals shares in Q2 2025, an estimated $3.01M.
  • Triasima Portfolio Management first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 12 quarters.
  • Triasima Portfolio Management's Vertex Pharmaceuticals position peaked at $6.49M in Q2 2023.
  • 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Triasima Portfolio Management's 13F filing for Q2 2025, filed 23 Jul 2025.